Motohiko Sato Selected Research

ethylenediamine (ethylenediamine dihydroiodide)

3/2018	Treatment of oral cancer using magnetized paclitaxel.
8/2017	The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
1/2016	Simultaneous hyperthermia-chemotherapy with controlled drug delivery using single-drug nanoparticles.
3/2015	A magnetic anti-cancer compound for magnet-guided delivery and magnetic resonance imaging.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Motohiko Sato Research Topics

Disease

9	Neoplasms (Cancer) 01/2022 - 05/2012
5	Hypoxia (Hypoxemia) 09/2020 - 01/2006
5	Ischemia 01/2018 - 01/2006
5	Heart Failure 01/2018 - 12/2004
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 05/2012
3	Familial Primary Pulmonary Hypertension 01/2021 - 09/2017
3	Pulmonary Hypertension 01/2021 - 09/2017
3	Hyperthermia 01/2016 - 05/2012
2	Cardiovascular Diseases (Cardiovascular Disease) 11/2021 - 01/2013
2	Vascular Remodeling 01/2021 - 09/2017
2	Mouth Neoplasms (Oral Cancer) 03/2018 - 05/2014
2	Cardiac Arrhythmias (Arrythmia) 01/2018 - 01/2016
2	Septic Shock (Toxic Shock Syndrome) 01/2018 - 01/2017
2	Reperfusion Injury 01/2014 - 07/2011
2	Congenital Heart Defects (Congenital Heart Defect) 01/2012 - 06/2010
2	Cardiomegaly (Heart Hypertrophy) 05/2011 - 09/2007
2	Hypertrophy 09/2007 - 01/2006
2	Leiomyosarcoma 01/2006 - 06/2004
1	Hypocalcemia 11/2021
1	Osteoporosis 11/2021
1	Pulmonary Arterial Hypertension 01/2021
1	COVID-19 01/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 01/2021
1	Critical Illness (Critically Ill) 01/2021
1	Carcinogenesis 01/2021
1	Disease Progression 06/2019
1	Hepatocellular Carcinoma (Hepatoma) 06/2019
1	Non-alcoholic Fatty Liver Disease 06/2019
1	Choroidal Neovascularization 01/2019
1	Endotoxemia 01/2018
1	Poisoning 08/2017
1	Pre-Eclampsia (Preeclampsia) 08/2017

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 06/2019 - 06/2004
7	GTP-Binding Proteins (G-Protein)IBA 01/2019 - 12/2002
4	IronIBA 03/2018 - 03/2015
4	ethylenediamine (ethylenediamine dihydroiodide)FDA Link 03/2018 - 03/2015
4	mu-oxo N,N'- bis(salicylidene)ethylenediamine ironIBA 03/2018 - 03/2015
4	CatecholaminesIBA 01/2018 - 01/2016
4	erythromycin propionate-N-acetylcysteinateIBA 01/2018 - 09/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 12/2016
3	Adenosine Triphosphate (ATP)IBA 01/2021 - 12/2016
3	Pharmaceutical PreparationsIBA 03/2018 - 03/2015
3	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2018 - 03/2015
3	CytokinesIBA 01/2018 - 01/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2017 - 05/2012
3	Messenger RNA (mRNA)IBA 12/2016 - 01/2006
3	Isoproterenol (Isoprenaline)FDA LinkGeneric 06/2014 - 12/2004
3	Heterotrimeric GTP-Binding Proteins (Heterotrimeric G-Proteins)IBA 01/2014 - 05/2011
3	Prostaglandins EIBA 01/2012 - 06/2010
2	AndrogensIBA 01/2022 - 01/2021
2	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 01/2019
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018 - 12/2016
2	MetalsIBA 08/2017 - 03/2015
2	disalicylaldehyde ethylenediamine (salen)IBA 08/2017 - 03/2015
2	ferric oxide (iron oxide)IBA 01/2016 - 05/2014
2	Adrenergic Agents (Adrenergic Drugs)IBA 01/2015 - 12/2004
2	Connexin 43 (Connexin43)IBA 01/2014 - 11/2009
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2022
1	Vitamin D FDA LinkGeneric 11/2021
1	romosozumabIBA 11/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	KD025IBA 01/2021
1	AntigensIBA 01/2021
1	Polypropylenes (Polypropylene)IBA 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	SiliconesIBA 01/2021
1	MonocrotalineIBA 01/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 01/2021
1	rho-Associated KinasesIBA 01/2021
1	KATP ChannelsIBA 09/2020
1	PotassiumIBA 09/2020
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 09/2020
1	Glucose (Dextrose)FDA LinkGeneric 09/2020
1	Glyburide (Glibenclamide)FDA LinkGeneric 09/2020
1	Blood Proteins (Serum Proteins)IBA 06/2019
1	inter-alpha-inhibitorIBA 06/2019
1	Biomarkers (Surrogate Marker)IBA 06/2019
1	Calcium-Sensing ReceptorsIBA 03/2019
1	Platelet-Derived Growth FactorIBA 01/2019
1	N- (2- hydroxy- 3- (2- cyano- 3- chlorophenoxy)propyl)- 1,1- dimethyl- 2- (2- nephthyl)ethylamineIBA 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 03/2018
1	Vidarabine (Vira-A)FDA Link 01/2018
1	Tadalafil (Cialis)FDA Link 09/2017
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 09/2017
1	Oxygen (Dioxygen)IBA 08/2017
1	NADPH Oxidases (NAD(P)H oxidase)IBA 08/2017
1	Human Serum Albumin FDA LinkGeneric 08/2017
1	Superoxides (Superoxide)IBA 08/2017

Therapy/Procedure

6	Therapeutics 01/2021 - 02/2003
5	Drug Therapy (Chemotherapy) 03/2018 - 05/2012
2	Induced Hyperthermia (Thermotherapy) 01/2016 - 05/2014
1	Renal Dialysis (Hemodialysis) 11/2021
1	Oxygenators 01/2021
1	Extracorporeal Membrane Oxygenation 01/2021
1	Mediterranean Diet 01/2021
1	Hepatectomy 06/2019
1	Chelation Therapy (Therapy, Chelation) 08/2017